Remove 2024 Remove Communication Remove Pharmaceutical Manufacturing
article thumbnail

Korea’s Minister of Food & Drug Safety: Addressing Medicines Supply Chain Resilience in the Asia-Pacific and Beyond

Quality Matters

Our team is diligent about maintaining consistent communication with manufacturers and other key stakeholders. We prioritize check-ins with stakeholders such as the Association of Medical Doctors and the Association of Pharmaceutical Manufacturers and Distributors regarding any issues with production.

article thumbnail

Pharma gives UCPMP the thumbs up, health activists cry foul

Express Pharma

Health activists raise doubts on pharma associations self-monitoring the code The notification of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 on March 12 has been welcomed by major pharma associations, while health activists allege it is a “whitewash.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Strengthening and transforming the pharmaceutical supply chain

European Pharmaceutical Review

Europe, too, has faced similar issues with its pharmaceutical supply chain, including critical shortages of antibiotics such as amoxicillin. Recent guidance published by the European Medicines Agency outlines measures that will be taken to increase preparedness for the autumn/winter 2023-2024.

article thumbnail

Instrument calibration procedure for pharmaceutical industry

GMPSOP

Instrument calibration procedure for pharmaceutical industry Pharmaceuticals quality assurance & validation procedures GMPSOP %title% Last Updated on March 20, 2024 Prev PREVIOUS POST Have you ever wondered if the scales at the grocery checkout show the right amount? Access to exclusive content for an affordable fee.

article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

This economic change impacts employment, income, industrial production, and more, and the pharmaceutical industry will not be exempt. by the end of 2023 and may continue to rise in 2024 to 5%. JP Morgan predicts that the US unemployment rate could rise to 4.3% million as part of the Build Back Better Regional Challenge.